Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: apixaban, warfarin, dabigatran, or rivaroxaban - Lip, G YH; Pan, X; Kamble, S (PLoS One, 2018)
, et al.